GRAIL Announces Appointment of Key Executives as Company Makes Continued Progress in Development of Early Detection Products July 9, 2018

GRAIL Announces Appointment of Key Executives as Company Makes Continued Progress in Development of Early Detection Products July 9, 2018

GRAIL, a company whose mission is to detect cancer early, when it can be cured, recently announced the appointment of several key leaders as it continues to build its executive team. George Golumbeski has been appointed as President and will also serve on GRAIL’s Board of Directors, effective August 1, 2018. Other appointees include Onaiza Cadoret-Manier as Chief Commercial Officer and Fred Kohler as Vice President of People. Angela Lai is being promoted to Chief Technology Officer, where she will oversee software engineering and data science at GRAIL.

Former President Ken Drazan has transitioned to an advisory role in order to spend more time pursuing his passion of helping early-stage startup companies secure funding and partnerships.

“As we make continued progress in the development of our product candidate for early detection of multiple cancer types, I am excited to welcome these exceptional leaders to the GRAIL team,” said GRAIL CEO Jennifer Cook.

George Golumbeski has more than 25 years in the biotechnology industry, most recently as executive vice president of business development with Celgene. He serves on the boards of several biotech companies.

Onaiza Cadoret-Manier brings more than 30 years of international commercial and operations experience, driving growth for Fortune 500 and startup companies. Most recently, she was vice president of the respiratory franchise at Genentech.

Fred Kohler came to GRAIL from a position at Roche, where he led transformation work globally. He specializes in organizational assessment and development, as well as talent and performance management.

Angela Lai joined GRAIL in 2016. Before her promotion to CTO, she served as vice president of clinical technology and was responsible for building the team developing software systems that support the company’s population-scale clinical studies.

Read the full announcement on BusinessWire.

Tags:
No Comments

Post a Comment